Amifostine as protective agent in cisplatin-based chemotherapy of advanced bladder cancer;Renale protektion unter MVEC-polychemotherapie beim fortgeschrittenen urothelkarzinom der harnblase durch amifostin

Urologe - Ausgabe A

Volumn 38, Issue 6, 1999, Pages 586-591

  Heidenreich, A ^a,d   Marx, F J ^b   Peters, H J ^c  

^a Medizinische Einrichtungen der Universitas t zu Köln   (Germany)

^b Stadt Krankenhaus Koln Holweide   (Germany)

^c St Elisabeth Hospital   (Germany)

^d UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Amifostine; Bladder cancer; Cisplatin; Cytoprotection; Nephrotoxicity

Indexed keywords

AMIFOSTINE; CISPLATIN; EPIRUBICIN; METHOTREXATE; VINBLASTINE;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAGNESIUM BLOOD LEVEL; MALE; NEPHROTOXICITY; NEUTROPENIA; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA;

EID: 0032753741     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001200050332     Document Type: Article

References (18)

1. Anand AJ, Bashey B (1993) Newer insights into cisplatin nephrotoxicity. Ann Pharmacother 27:1519
2. Bokemeyer C, Hartmann JT, Fels L, Knop S, Brugger W, Stolte H, Kranz L (1997) Amifostine protects against early cisplatin induced renal damage and enhances CD34 + cell numbers for PBSC collection. Proc Am Soc Clin Oncol 16:166
3. Capizi RL (1994) Protection of normal tissues from the cytotoxic effects of chemotherapy by amifostine (Ethyol): clinical experiences. Semin Oncol 21 [Suppl 11]: 8-15
4. Glover D, Click JH, Weiler C, Fox K, Guerry D (1987) WR-2721 and high dose cisplatin: an active combination in the treatment of metastatic melanoma. J Clin Oncol 5:574-578
5. Kemp G, Rose P, Lurain J, Berman M, Manetta A, Roullet B, Homesly H, Belpomme D, Click J Amifostine pretreatment for protection against cyclophosphamide induced and cisplatin induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 14:2101-2112
6. Martinez-Pineiro JA, Martinez-Pineiro L (1998) The role of neoadjuvant chemotherapy for invasive bladder cancer. Br J Urol 82:33-42
7. Mollmann JE (1990) Cisplatin neurotoxicity. N Engl J Med 11:126
8. Planting AST, Vermorken JB, Catimel G, DeMUIder PHM, De Graeff A, Oster W, Verdonk MER (1995) Randomized phase II study of weekly cisplatin with or without amifostine in patients with advanced head and neck cancer. Eur J Cancer 31 A: Abstract 392
9. Rübben H, Otto T (1997) Harnblasenkarzinom. In: Rübben H (Hrsg) Uroonkologie. Springer, Berlin Heidelberg New York, S 85-178
10. Schiller JH, Storer B, Berlin J (1996) Amifostine, cisplatin, and vinblastine in metastatic non-small-cell lung cancer: a report of high response rates and prolonged survival. J Clin Oncol 14:1913-1924
11. Spencer CM, Goa KL (1995) Amifostine: a review of its pharmakodynamic and pharmakokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector. Drugs 50:1001-1031
12. Sternberg CN, Yagoda A, Scher HI, Watson RC, Ahmed T, Weiselberg LR, Geller N, Hollander PS, Herr HW, Sogani PC, Morse MJ, Whitmore WF (1985) Preliminary results of MVAC (methotrexate, vinblastine, doxorubucin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 133:403-407
13. Stöckle M, Wellek S, Meyenburg W, Voges GE, Fischer U, Gertenbach U, Thüroff JW, Huber C, Hohenfellner R (1996) Radical cystectomy with ot without adjuvant polychemotherapy for non-organ-confined transitional cell carcinoma of the urinary bladder: prognostic impact of lymph node involvement. Urology 48:868-875
14. Stoter G, Splinter TAW, Child JA, Fosså SD, Denis L, Oosterom AT, Pauw M, Sylvester R (1997) Combination chemotherapy with cisplatin and methotrexate in advanced transitional cell cancer of the bladder. J Urol 137:663-667
15. Treskes M, Nijtmans LG, Fichtinger SA (1992) Effects of the modulating agent WR-2721 and its main metabolites on the formation and stability of cisplatin-DNA adducts invitro in comparison to the effects of thiosulphate and diethyldithiocarbamate. Biochem Pharmacol 43:1013-1019
16. Vijgh WJF, Peters GJ (1994) Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (Ethyol): preclinical aspects. Semin Oncol 21 [Supplm 11]:2-7
17. Wittenkeller J, Bittner G, Schiller JH (1994) Amifostine (WR-2721) enhances cisplatin/ vinblastine effect on nonsmall cell lung carcinoma cells in vivo but not in vitro. Proc Am Assoc Cancer Res 35:386
18. Yuhas JM, Culo F (1980) Selective inhibition of the nephrotoxicity of cos-dichlordiammineplatinum (II) by wr-2721 without altering its antitumor properties. Cancer Treat Rep 64:57-64